Cargando…
Day-to-day variations during clinical drug monitoring of morphine, morphine-3-glucuronide and morphine-6-glucuronide serum concentrations in cancer patients. A prospective observational study
BACKGROUND: The feasibility of drug monitoring of serum concentrations of morphine, morphine-6-glucuronide (M6G) and morphine-3-glucuronide (M3G) during chronic morphine therapy is not established. One important factor relevant to drug monitoring is to what extent morphine, M6G and M3G serum concent...
Autores principales: | Klepstad, Pål, Hilton, Priscilla, Moen, Jorunn, Kaasa, Stein, Borchgrevink, Petter C, Zahlsen, Kolbjørn, Dale, Ola |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2004
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC526195/ https://www.ncbi.nlm.nih.gov/pubmed/15461818 http://dx.doi.org/10.1186/1472-6904-4-7 |
Ejemplares similares
-
Influence of Morbid Obesity on the Pharmacokinetics of Morphine, Morphine-3-Glucuronide, and Morphine-6-Glucuronide
por: de Hoogd, Sjoerd, et al.
Publicado: (2017) -
Pharmacokinetics of Morphine, Morphine-3-Glucuronide and Morphine-6-Glucuronide in Terminally Ill Adult Patients
por: Franken, Linda G., et al.
Publicado: (2015) -
Morphine-3-Glucuronide, Physiology and Behavior
por: Gabel, Florian, et al.
Publicado: (2022) -
Explanation at the opioid receptor level for differing toxicity of morphine and morphine 6-glucuronide.
por: Hucks, D., et al.
Publicado: (1992) -
Morphine-induced hyperalgesia involves mu opioid receptors and the metabolite morphine-3-glucuronide
por: Roeckel, Laurie-Anne, et al.
Publicado: (2017)